Atara Biotherpeutics reported a similar net loss in the third quarter of 2022 as it had the previous year, but the possible approval of its first product in Europe within the next two quarters has the company in good spirits. Atara, a South San Francisco-based immunotherapy company with its major operations in Thousand Oaks, reported…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
